What are you searching for?

Sign in
Breaking News, Promotions & Moves

Achillion Pharmaceuticals Appoints EVP & COO

Paul Firuta has 27 years of experience building commercial organizations & launching products targeting rare diseases

Achillion Pharmaceuticals announced the appointment of Paul Firuta to the position of executive vice president and chief operating officer effective immediately. 

 
Mr. Firuta, with 27 years of experience successfully building commercial organizations and launching products targeting rare diseases, will assume responsibility for leading Achillion’s commercial strategy and operations, market access, pharmaceutical sciences & manufacturing, project management and patient advocacy. 

“Paul’s operational leadership and successful track record launching rare disease treatments, including the complement inhibitor Cinryze®, will greatly benefit Achillion as we accelerate our factor D clinical programs and prepare for registrational trials and commercialization,” commented Joseph Truitt, President and chief executive officer of Achillion.
 
“It is a very exciting time to be joining Achillion as Chief Operating Officer,” stated Mr. Firuta. “Achillion is uniquely positioned to make a difference in the lives of patients with devastating complement mediated rare diseases for which few therapeutic options exist. I look forward to leading the Achillion teams in advancing our complement factor D portfolio into planned phase 3 development.”

Mr. Firuta joins Achillion from uniQure N.V.  where he held the position of chief commercial officer. Over the course of his career, Mr. Firuta has held various leadership roles at biopharmaceutical companies including: Vice President and General Manager, Americas at ViroPharma, Inc. leading the U.S. commercial operations for CINRYZE and VANCOCIN, representing over $400 million in U.S. revenue.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters